US 9492564
Dual specific immunotoxin for brain tumor therapy
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 9492564 (Dual specific immunotoxin for brain tumor therapy) held by The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health
- Grant date
- Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K38/00, A61K39/39558